New AZ chief gets $6.4M to make up for Roche forfeit

AstraZeneca ($AZN) didn't send flowers to Pascal Soriot to woo him away from Roche ($RHHBY). No, its new chief executive got something much more valuable in the bargain: A £4 million ($ 6.44 million) payment. It's not exactly a signing bonus, though. The $6.44 million compensates Soriot for his loss of long-term incentive compensation from Roche. Story

Suggested Articles

Disarm Therapeutics signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant, as its full-time CEO.

Pact Pharma launched a phase 1 trial of a technology designed to attack solid tumors with CAR-T cells tailored to individual patients.

Intec's candidate uses a drug delivery system designed to improve on Merck’s Sinemet but was unable to beat the product in a late-phase test.